Literature DB >> 15885656

Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.

Leonor Sterin-Borda1, Claudia F Del Zar, Enri Borda.   

Abstract

In this study, we have determined the contractile effects of CB1 and CB2 cannabinoid receptor activation on rat isolated atria and the different signaling pathways involved. Anandamide did not has significantly effect on atria contractility, however, the treatment with both CB1 (AM251) or CB2 (AM630) receptor antagonists, the endocannabinoids triggered stimulation or inhibition on contractility respectively. The ACEA stimulation of CB1 receptor exerted decrease on contractility, that significantly correlated with the decrement of cAMP and the stimulation of nitric oxide synthase (NOS) and the accumulation of cyclic GMP (cGMP). On the contrary, JWH 015 stimulation of CB2 receptor triggered positive contractile response that significantly correlated with the increase cAMP production. The inhibiton of adenylate cyclase activity impaired the JWH 015 activation of CB1 receptor induced positive contractile effect, while inhibitors of phospholipase C (PLC), NOS and soluble nitric oxide (NO)-sensitive guanylate cyclase blocked the dose-response curves of ACEA on contractility. Those inhibitors also attenuated the CB1 receptor-dependent increase in activation of NOS and cGMP accumulation. These results suggest that CB2 receptor agonist mediated positive contractile effect associated with increased production on cAMP while CB1 receptor agonist mediated decrease on contractility associated with decreased cAMP accumulation and increase production of NO and cGMP; that occur secondarily to stimulation of PLC, NOS and soluble guanylate cyclase. Data give pharmacological evidence for the existence of functional CB1 and CB2 cannabinoid receptors in rat isolated atria and may contribute to a better understanding the effects of cannabinoids in the cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885656     DOI: 10.1016/j.bcp.2005.03.027

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Peripheral cannabinoid receptor, CB2, regulates bone mass.

Authors:  Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; Raphael Mechoulam; Andreas Zimmer; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.

Authors:  Anna Pędzińska-Betiuk; Jolanta Weresa; Marek Toczek; Marta Baranowska-Kuczko; Irena Kasacka; Ewa Harasim-Symbor; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2017-05-31       Impact factor: 8.739

Review 4.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

5.  Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells.

Authors:  Jenelle D Jones; Skyla T Carney; Kent E Vrana; Derek C Norford; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2007-07-12       Impact factor: 5.250

6.  Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats.

Authors:  A J Wheal; T Bennett; M D Randall; S M Gardiner
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

7.  Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon.

Authors:  Nicholas M Hinds; Katja Ullrich; Scott D Smid
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

8.  Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.

Authors:  Svetlana Slavic; Dilyara Lauer; Manuela Sommerfeld; Ulrich Rudolf Kemnitz; Aleksandra Grzesiak; Manuela Trappiel; Christa Thöne-Reineke; Johannes Baulmann; Ludovit Paulis; Kai Kappert; Ulrich Kintscher; Thomas Unger; Elena Kaschina
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

9.  Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Ex Vivo Rat Model.

Authors:  Danielle I Lee; Michael Murninkas; Sigal Elyagon; Yoram Etzion; Hope D Anderson
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 10.  Cannabinoid Receptors in Myocardial Injury: A Brother Born to Rival.

Authors:  Xinru Tang; Zheng Liu; Xiaoqing Li; Jing Wang; Liliang Li
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.